syn818
BRCA 1 /2 and / or HRD
Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the BRCA 1 /2 and / or HRD cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Phase 2 | BB |
Carboplatin GBG Forschungs GmbH | Phase 2 | B |
Epirubicin GBG Forschungs GmbH | Phase 2 | B |
Cyclophosphamide GBG Forschungs GmbH | Phase 2 | B |
Same molecule, other indications
syn818 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →